Skip to content
The Nexus
DossierENTITY

Bloomberg Law

Coverage of Bloomberg Law in the Nexus archive.

Earliest in view: May 6 · 13:34 UTCMost recent: Jun 22 · 13:00 UTC
Co-mentioned in this coverage
Supreme Courtorganization1ACLUorganization1Cecillia Wangperson1Arkansasplace1Texasplace1Arizonaplace1Pennsylvaniaplace1Emory University’s Supreme Court Advocacy Programorganization1NPRorganization1SECorganization1tokenized assetstopic1third-party tokenstopic1Pharmaceutical Research and Manufacturers of Americaorganization1340B Drug Pricing Programtopic1US Food and Drug Administrationorganization1Vinay Prasadperson1Alliance for Regenerative Medicineorganization1Medicaidtopic1
Recent coverage
  • POLITICSJun 22 · 13:00 UTCSCOTUSBLOG
    A new wave of election cases

    The Supreme Court is preparing to issue 17 opinions by early July, with at least two opinion announcement days this week. The court faces new election-related cases involving state laws on voting rules, including challenges to laws in Arkansas, Texas, Arizona, and Pennsylvania. Additionally, law students are petitioning the court to address workplace protections for federal judiciary employees.

  • BUSINESSMay 22 · 19:29 UTCTHE BLOCK
    SEC delays tokenized asset exemption amid concerns over third-party tokens: Bloomberg Law

    The SEC has delayed its planned exemption for tokenized assets, which was expected to clarify the agency's regulatory stance on this emerging asset class. The delay comes amid regulatory concerns over third-party tokens, according to Bloomberg Law reporting.

  • HEALTHMay 6 · 13:34 UTCSTAT NEWS
    STAT+: Pharmalittle: We’re reading about a PhRMA ad campaign aimed at 340B, sales of Novo’s obesity pill, and more

    The Pharmaceutical Research and Manufacturers of America is launching a seven-figure ad campaign targeting the 340B Drug Pricing Program, while the US Food and Drug Administration has seen an increase in rejection rates for cell and gene therapies. The program requires manufacturers to provide drugs at reduced prices to health providers caring for low-income patients. The ad campaign aims to manipulate the program's benefits.